@entity407 is common in transplant @entity1 . Although a causal relationship to the use of @entity205 is accepted, additional risk factors are as yet unidentified. Eighty-five liver transplant recipients treated with standard triple immunosuppression with a survival of at least 6 months were evaluated. Pretransplantation and posttransplantation variables were analyzed as predictive @entity407 . Serum @entity165 and @entity412 levels were considered elevated if they were > 250 mg/dL and > 150 mg/dL, respectively. Before and after transplantation, @entity407 occurred in 8% (95% confidence interval [CI], 3% to 16%) and 66% (95% CI, 55% to 76%), respectively. After transplantation, 47% (95% CI, 36% to 58%) of the @entity1 had isolated high @entity412 levels, 12% (95% CI, 6% to 21%) had both elevated @entity165 and @entity412 levels, and 7% (95% CI, 3% to 15%) had isolated elevated @entity165 levels. @entity2298 occurred early after transplantation (67% by first month) and persisted nearly unchanged throughout the first year. In contrast, @entity165 levels increased with time (5%, 13%, and 27% at 1, 3, and 6 months, respectively). In univariate analysis, factors predictive of @entity1007 included female sex, pretransplantation @entity409 , pretransplantation @entity165 levels > 141 mg/dL, and > 3 @entity1667 "boluses." In multivariate analysis, only a pretransplantation @entity165 level of > 141 mg/dL (odds ratio [OR], 5.5; 95% CI, 1.4 to 21) was an independent risk factor. Risk factors associated with @entity2298 included @entity99 (OR, 6.8; 95% CI, 1.2 to 40) and posttransplantation @entity8 (OR, 5.4; 95% CI, 1.9 to 15.4). @entity407 is a frequent finding in liver transplant recipients, and @entity2298 is the most common abnormality. @entity2298 can be predicted on the basis of @entity8 . Pretransplant serum @entity165 level is an independent risk factor for posttransplant @entity1007 .

XXXX in liver transplant recipients: prevalence and risk factors.

@entity407 :: ('MESH:D006949', 'Disease') :: ['Hyperlipidemia', 'factors of posttransplantation hyperlipidemia', 'hyperlipidemia'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity2298 :: ('MESH:D015228', 'Disease') :: ['Hypertriglyceridemia', 'hypertriglyceridemia'] @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal dysfunction', 'pretransplant hepatocellular disease and posttransplant renal dysfunction'] @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia'] @entity409 :: ('MESH:D008107', 'Disease') :: ['cholestatic liver disease'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride'] @entity99 :: ('MESH:D056486', 'Disease') :: ['pretransplantation hepatocellular liver disease'] @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']
@entity407 :: (MESH:D006949,Disease) :: ['Hyperlipidemia']
